This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Dornase alfa

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • dornase alfa is a genetically engineered version of human DNAase
  • the sputum of patients with cystic fibrosis (CF) contains large amounts of DNA - the viscoelastic property of sputum in CF patients is due to the inherent viscosity of DNA, and the mucus glycoproteins
  • nebulised dornase alfa is a well tolerated and safe treatment option in CF - dornase alfa reduces the viscosity of CF sputum by decreasing DNA strand size
  • there is evidence of medium-term improvement in lung function

NICE state that (1):

  • a mucoactive agent should be offered to people with cystic fibrosis who have clinical evidence of lung disease

  • rhDNase (dornase alfa; recombinant human deoxyribonuclease) should be offered as the first choice of mucoactive agent

  • if clinical evaluation or lung function testing indicates an inadequate response to rhDNase, consider both rhDNase and hypertonic sodium chloride or hypertonic sodium chloride alone

  • consider mannitol dry powder for inhalation for children and young people who cannot use rhDNase and hypertonic sodium chloride because of ineligibility, intolerance or inadequate response.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.